Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Results 1-24 of 24 for your search:
Start Over
Vaccine Therapy in Treating Patients with Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
Status: Enrolling by invitation
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 6304, NCI-2016-00895, NCT00194714
Vaccine Therapy with or without Polysaccharide-K in Treating Patients with Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7866, NCI-2013-01377, 135, 7866/135, NCT01922921
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Stage IV Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J0947, NCI-2010-02004, NA_00024527, JHOC-J0947, GENENTECH-JHOC-J0947, NCT00971737
Nelipepimut-S plus GM-CSF Vaccine Therapy in Treating Patients with Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2016-0164, NCI-2015-02189, N01-CN-2012-00034, MDA2014-04-02, NCT02636582
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: FRV-002, NCI-2016-00538, NCT02593227
Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients with Triple Negative Breast Cancer
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RU011501I, NCI-2016-01878, NCT03012100
Combined Vaccine Therapy in Treating Patients with Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-09138, NCI-2011-00920, NCT01376505
Vaccine Therapy and Basiliximab in Treating Patients With Stage IV Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 03111, NCI-2013-00879, NCT01660529
Vaccine Therapy in Treating Patients with HER2-Positive Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0016, NCI-2013-01564, 130016, P12990, NCT01730118
Vaccine Therapy in Treating Patients with Stage I-III HER2 Positive Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18776, NCI-2014-00878, 818561, NCT02110199, UPCC 26113, NCT02061423
Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ID-LV305-2013-001, NCI-2014-01153, NCT02122861
Vaccine Therapy in Treating Patients with HER2-Negative Stage III-IV Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9140, NCI-2014-01070, 137, NCT02157051
Mammaglobin-A DNA Vaccine in Treating Patients with Newly Diagnosed Breast Cancer Undergoing Endocrine Therapy before Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201407100, NCI-2014-01457, 14-x092, NCT02204098
INO-1400 Vaccine Alone or in Combination with INO-9012 Followed by Electroporation in Treating Patients with Breast, Lung, or Pancreatic Cancer at High Risk of Relapse after Surgery and Standard Treatment
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC #22913 / Inovio TRT-00, NCI-2015-00389, 821038, UPCC 22913, NCT02327468
Personalized DNA Vaccine in Treating Patients with Triple-Negative Breast Cancer Following Chemotherapy
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201505074, NCI-2015-00827, NCT02348320
Personalized Vaccine Therapy in Treating Patients with Triple-Negative Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201506113, NCI-2015-01050, NCT02427581
Vaccine Therapy and Pembrolizumab in Treating Patients with Advanced Solid Tumors That Have Failed Prior Therapy and That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15002, NCI-2015-00653, 116634, 122284, 122771, 124524, NCT02432963
Vaccine Therapy in Preventing Cancer Recurrence in Patients with Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
Status: Active
Phase: Phase I
Type: Prevention, Treatment
Age: 18 and over
Trial IDs: UWI4090, NCI-2016-00581, 9626, N01-CN-2012-00033, UWI2014-03-01, NCT02780401
Vaccine Therapy with or without Durvalumab in Treating Patients with Stage II-III Triple Negative Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-132, NCI-2016-01368, NCT02826434
hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TRT-001, NCI-2017-00011, NCT02960594
PGV001 in Treating Patients with Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-1811, NCI-2017-01044, NCT02721043
Vaccine Therapy in Treating Patients With Breast Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 12911, NCI-2010-00461, Breast 37, NCT00892567
Vaccine Therapy in Treating Patients with Stage IB-IIIA Breast Cancer
Status: Temporarily closed
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Breast41, NCI-2014-02151, 1134, NCT01532960
Dendritic Cell Vaccine and Gemcitabine Hydrochloride in Treating Patients with Metastatic Breast Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CASE 3113, NCI-2014-00265, 046203, 3113, NCT02479230
Start Over